Clinical Trials Logo

Clinical Trial Summary

This is a Phase I, single-center, double-blind, placebo-controlled dose escalation trial of three dose cohorts (A: 0.033 mg/kg, B: 0.165 mg/kg, and C: 0.33 mg/kg). The purpose of this study is to evaluate the safety and tolerability of NTM-1633 in healthy adults. This is a first-in-human study consisting of three cohorts of eight subjects each. Dosing for each cohort is as follows: Two sentinel subjects will be administered a single 1-hour infusion (one NTM-1633, one placebo). No more than two subjects per day thereafter (at least 24 hrs will elapse between the dosing of each two subjects) will be dosed in the same manner until all subjects are dosed. Dose escalation will not occur until safety data through Day 8 is reviewed by the Safety Review Committee (SRC). Objective dose-escalation criteria and safety evaluations will be utilized. The study duration will be for approximately 8 months. Subjects in Cohort A will participate for approximately 17 weeks and Subjects in Cohorts B and C will participate approximately 21 weeks. Primary Objective: To assess the safety and tolerability of escalating doses of NTM-1633 administered intravenously in healthy adults.


Clinical Trial Description

This is a Phase I, single-center, double-blind, placebo-controlled dose escalation trial of three dose cohorts (A: 0.033 mg/kg, B: 0.165 mg/kg, and C: 0.33 mg/kg). The purpose of this study is to evaluate the safety and tolerability of NTM-1633 in healthy adults. This is a first-in-human study consisting of three cohorts of eight subjects each. Dosing for each cohort is as follows: Two sentinel subjects will be administered a single 1-hour infusion (one NTM-1633, one placebo). No more than two subjects per day thereafter (at least 24 hrs will elapse between the dosing of each two subjects) will be dosed in the same manner until all subjects are dosed. Dose escalation will not occur until safety data through Day 8 is reviewed by the Safety Review Committee (SRC). Objective dose-escalation criteria and safety evaluations will be utilized. The study duration will be for approximately 8 months. Subjects in Cohort A will participate for approximately 17 weeks and Subjects in Cohorts B and C will participate approximately 21 weeks. Primary Objective: To assess the safety and tolerability of escalating doses of NTM-1633 administered intravenously in healthy adults. Secondary Objectives: 1) To assess the pharmacokinetic characteristics of NTM-1633 following a single intravenous administration; 2) To assess the immunogenicity of NTM-1633 following a single intravenous administration. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03603665
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status Completed
Phase Phase 1
Start date September 25, 2018
Completion date June 11, 2019

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04550793 - Using Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
Completed NCT01441557 - Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism Phase 2/Phase 3
Recruiting NCT05769478 - Effect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA Phase 1
Withdrawn NCT01940315 - Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B Phase 3
Enrolling by invitation NCT02051062 - BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients Phase 4
Completed NCT02055183 - BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
Completed NCT01357213 - Phase 1 PK Study of XOMA 3AB Phase 1
Completed NCT03676634 - Tolerability and Immunogenicity of rBV A/B for the Production of BabyBIG® Phase 2
Completed NCT00314080 - Treatment of Survivors After Botulism Outbreak N/A
Not yet recruiting NCT06112834 - Tolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG® Phase 2
Completed NCT00348426 - Botulism Outbreak in Thailand (Episode II) Phase 4
Completed NCT00004401 - Study of Human Botulism Immunoglobulin in Infants With Botulism N/A
Completed NCT01701999 - Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid Phase 2
Completed NCT02779140 - Phase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632 Phase 1